Literature DB >> 28410297

Identification of Immunogenic Epitopes by MS/MS.

Moreno Di Marco1, Janet Kerstin Peper, Hans-Georg Rammensee.   

Abstract

The interrogation of cell surface-presented immunogenic epitopes is of great importance to differentiate diseased cells in consequence to malignant transformation or viral infections. On the basis of this knowledge, next-generation immunotherapies against cancers, autoimmunity, or infectious diseases can be developed. The identification of altered peptide repertoires of transformed cells renders mass spectrometry-based analysis indispensable. This is evident considering the low correlation of gene or protein expression alterations, respectively, with changes in the peptide repertoire rendering those analyses less informative. Nevertheless, immunogenicity of peptides appearing to be exclusively found on diseased cells has to be finally proven in T cell-based assays. This review highlights the capabilities and limitations of mass spectrometry in the identification of entire immunopeptidomes, as well as individual potential immunogenic epitopes with a strong focus on cancer. Furthermore, an overview of state-of-the-art immunogenicity screens is presented.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28410297     DOI: 10.1097/PPO.0000000000000252

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  8 in total

1.  Predicted MHC peptide binding promiscuity explains MHC class I 'hotspots' of antigen presentation defined by mass spectrometry eluted ligand data.

Authors:  Emma Christine Jappe; Jens Kringelum; Thomas Trolle; Morten Nielsen
Journal:  Immunology       Date:  2018-03-08       Impact factor: 7.397

2.  Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.

Authors:  Sebastian Kruse; Marleen Büchler; Philipp Uhl; Max Sauter; Philipp Scherer; Tammy C T Lan; Samantha Zottnick; Alexandra Klevenz; Ruwen Yang; Frank Rösl; Walter Mier; Angelika B Riemer
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

Review 3.  Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.

Authors:  Laura Santambrogio; Hans-Georg Rammensee
Journal:  Immunogenetics       Date:  2018-10-20       Impact factor: 2.846

4.  Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.

Authors:  Annika Nelde; Yacine Maringer; Tatjana Bilich; Helmut R Salih; Malte Roerden; Jonas S Heitmann; Ana Marcu; Jens Bauer; Marian C Neidert; Claudio Denzlinger; Gerald Illerhaus; Walter Erich Aulitzky; Hans-Georg Rammensee; Juliane S Walz
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

5.  IntroSpect: Motif-Guided Immunopeptidome Database Building Tool to Improve the Sensitivity of HLA I Binding Peptide Identification by Mass Spectrometry.

Authors:  Le Zhang; Geng Liu; Guixue Hou; Haitao Xiang; Xi Zhang; Ying Huang; Xiuqing Zhang; Bo Li; Leo J Lee
Journal:  Biomolecules       Date:  2022-04-14

6.  Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.

Authors:  Barbara Ziffels; Francesca Pretto; Dario Neri
Journal:  Immunotherapy       Date:  2018-03       Impact factor: 4.196

Review 7.  Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health.

Authors:  Mar Forner; Rodrigo Cañas-Arranz; Sira Defaus; Patricia de León; Miguel Rodríguez-Pulido; Llilianne Ganges; Esther Blanco; Francisco Sobrino; David Andreu
Journal:  Vaccines (Basel)       Date:  2021-05-08

8.  Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.

Authors:  Anna Reustle; Moreno Di Marco; Carolin Meyerhoff; Annika Nelde; Juliane S Walz; Stefan Winter; Siahei Kandabarau; Florian Büttner; Mathias Haag; Linus Backert; Daniel J Kowalewski; Steffen Rausch; Jörg Hennenlotter; Viktoria Stühler; Marcus Scharpf; Falko Fend; Arnulf Stenzl; Hans-Georg Rammensee; Jens Bedke; Stefan Stevanović; Matthias Schwab; Elke Schaeffeler
Journal:  Genome Med       Date:  2020-03-30       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.